Archives
-
RIPA Lysis Buffer: Product Overview
2026-10-08
RIPA Lysis Buffer Strong (SKU K1120) is an APExBIO detergent-based cell and tissue lysis product described for protein extraction without included protease or phosphatase inhibitors. No matched paper evidence was provided to independently establish performance, assay compatibility, or comparative benefits.
-
Taltirelin Acetate: Reading the Evidence
2026-10-07
Taltirelin acetate is a long-acting TRH analog with a distinctive preclinical evidence profile in dopaminergic neuroprotection. This article separates demonstrated findings from mechanistic hypotheses and clarifies what the research can—and cannot—support across Parkinson’s disease, itch, sleep, and formulation studies.
-
25-Hydroxycholesterol Reprograms Immunosuppressive TAMs
2026-10-07
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal lipid sensing to AMPKα–STAT6 signaling in tumor-associated macrophages. The study shows that disrupting this pathway can increase antitumor T-cell activity and improve responses to PD-1 blockade in preclinical models, while also defining important boundaries for translation.
-
Optimizing iPSC-Derived Platelet Production
2026-10-06
Yue and colleagues describe an optimized differentiation scheme that coordinates embryoid-body input, human platelet lysate medium, small-molecule signal replacement, and megakaryocyte maturation. The reported platform reached 19-day differentiation, 14.9 platelets per iPSC, functional clot activity in vitro, and a 58.3% cost reduction, while remaining subject to important scale-up and translational limitations.
-
GW4064 and FXR Signaling in Metabolic Research
2026-10-06
GW4064 is a reported non-steroidal FXR agonist used as a research tool for studying bile acid, cholesterol, and triglyceride regulation. This overview separates supplier-reported potency and animal findings from peer-reviewed evidence on FXR-related cholestatic injury, while emphasizing assay context, translational limits, and the absence of evidence for clinical efficacy.
-
NEDD4L, PRMT5, and Colorectal Cancer Liver Metastasis
2026-10-05
The 2025 Advanced Science study identifies NEDD4L as an E3 ubiquitin ligase that suppresses colorectal cancer liver metastasis by promoting PRMT5 degradation and weakening AKT/mTOR signaling. Its in vivo screening strategy links a metastasis phenotype to a specific ubiquitin-dependent mechanism, while the preclinical design also defines important limits on clinical interpretation.
-
Thermal-Protective Hydrogel for Tumor Ablation
2026-10-05
The ACS Applied Materials & Interfaces study presents MR@CaP@HA, an injectable hydrogel designed to protect nearby tissue during thermal ablation while releasing mitoxantrone and R-848 in response to tumor-associated conditions. Reported results connect thermal insulation with immunogenic cell death, dendritic-cell maturation, macrophage polarization, and complete tumor eradication in a subset of treated animals, while also underscoring the need for further translational validation.
-
GSK J4 HCl: From Chromatin to Translation
2026-10-04
GSK J4 HCl offers a useful chemical-probe framework for connecting JMJD3 biology with inflammatory signaling, cancer models, and epigenetic regulation research. This article separates vendor-reported activity from peer-reviewed evidence and defines the translational questions that remain open.
-
Tetramethylrhodamine Ethyl Ester: Interpreting ΔΨm
2026-10-03
Tetramethylrhodamine ethyl ester perchlorate is more than a mitochondrial imaging dye: it is a reporter of electrochemical state that must be interpreted alongside apoptosis, ROS, and respiratory biology. This article connects TMRE-based measurements with a recent preprint on caspase-3, NDUFS1, and ERO1α while clarifying evidence boundaries.
-
Inducing Right Ventricular-Like Cardiomyocytes
2026-10-02
Saito et al. developed a modified hPSC cardiac differentiation strategy that increases the production of right ventricular-like cardiomyocytes by directing progenitors toward an anterior second heart field identity. The resulting cells showed chamber-associated molecular and functional differences, creating a more precise platform for modeling right-sided cardiac disease.
-
GSK 2837808A: LDHA Workflow for Cancer Metabolism
2026-10-01
Build a controlled lactate and glucose-flux workflow around GSK 2837808A, a potent lactate dehydrogenase A inhibitor with strong biochemical selectivity. The guide separates established hepatocellular carcinoma evidence from hypothesis-generating applications in colorectal cancer and immune-metabolism studies.
-
Bortezomib (PS-341): Proteasome Assay Workflows
2026-10-01
Build reproducible Bortezomib workflows for reversible 20S proteasome inhibition, apoptosis assays, and cancer-cell response profiling. The guide also shows how to pair proteostasis measurements with mitochondrial metabolism readouts inspired by recent TCAIM–OGDH research, without overstating the evidence.
-
PEG 400, Quercetin, and Transporter-Mediated Exposure
2026-09-30
The reference study shows that PEG 400 substantially increases rat exposure to quercetin and quercetin-3-O-glucuronide while changing their tissue distribution and anti-inflammatory activity. By combining pharmacokinetics, spatial mass spectrometry imaging, enzyme assays, transporter models, and paw-edema testing, it proposes a coordinated solubility, glucuronidation, and efflux mechanism rather than attributing the effect to one process.
-
Soluble PD-L1 in Glioma: Wnt/β-Catenin Mechanism
2026-09-30
The reference study identifies glioma cells as a source of soluble PD-L1 and links its production to Wnt/β-catenin signaling. Its findings connect circulating sPD-L1 with tumor aggressiveness and reduced CD8+ T-cell activity, while supporting combined Wnt and PD-L1 blockade as a potentially useful therapeutic strategy.
-
GSK 2837808A in LDHA Metabolism Workflows
2026-09-29
GSK 2837808A provides a selective way to test whether LDHA-dependent lactate production drives metabolic and immune phenotypes. This workflow connects validated hepatocellular carcinoma use with hypothesis-driven colorectal cancer assays while emphasizing exposure control, orthogonal readouts, and pharmacokinetic limitations.